Etifoxine-d5

Etifoxine-d5 is the deuterium labeled Etifoxine. Etifoxine, a non-benzodiazepine GABAergic compound, is a positive allosteric modulator of α1β2γ2 and α1β3γ2 subunit-containing GABAA receptors. Etifoxine reveals anxiolytic and anticonvulsant properties in rodents[1][2][3].

Product Specifications

CAS Number

[1346598-10-4]

UNSPSC

12352005

Target

GABA Receptor

Type

Isotope-Labeled Compounds

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Solubility

10 mM in DMSO

Smiles

[2H]C1=C(C2(C)OC(NCC)=NC3=CC=C(Cl)C=C32)C([2H])=C(C([2H])=C1[2H])[2H]

Molecular Formula

C17H12D5ClN2O

Molecular Weight

305.81

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Marc Verleye, et al. Effects of etifoxine on ligand binding to GABA (A) receptors in rodents. Neurosci Res. 2002 Oct;44 (2) :167-72.|[3]Alain Hamon, et al. The modulatory effects of the anxiolytic etifoxine on GABA (A) receptors are mediated by the beta subunit. Neuropharmacology. 2003 Sep;45 (3) :293-303.|[4]Marc Verleye, et al. Differential effects of etifoxine on anxiety-like behaviour and convulsions in BALB/cByJ and C57BL/6J mice: any relation to overexpression of central GABAA receptor beta2 subunits? Eur Neuropsychopharmacol. 2011 Jun;21 (6) :457-70.